Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization, Breast Cancer Research and Treatment, vol.353, issue.Suppl 4, pp.511-527, 2010. ,
DOI : 10.1007/s10549-009-0433-y
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer, Nature Reviews Clinical Oncology, vol.24, issue.1, pp.22-36, 2010. ,
DOI : 10.1038/nrclinonc.2009.186
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial, Clin Cancer Res, vol.8, pp.1073-1079, 2002. ,
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer, Journal of Clinical Oncology, vol.21, issue.6, pp.976-983, 2003. ,
DOI : 10.1200/JCO.2003.02.063
Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, Journal of Clinical Oncology, vol.23, issue.16, pp.3686-3696, 2005. ,
DOI : 10.1200/JCO.2005.10.517
Adjuvant Docetaxel for Node-Positive Breast Cancer, New England Journal of Medicine, vol.352, issue.22, pp.2302-2313, 2005. ,
DOI : 10.1056/NEJMoa043681
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, Journal of Clinical Oncology, vol.24, issue.36, pp.5664-5671, 2006. ,
DOI : 10.1200/JCO.2006.07.3916
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial, The Lancet, vol.373, issue.9676, pp.1681-1692, 2009. ,
DOI : 10.1016/S0140-6736(09)60740-6
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer, New England Journal of Medicine, vol.354, issue.8, pp.809-820, 2006. ,
DOI : 10.1056/NEJMoa053028
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer, Journal of Clinical Oncology, vol.28, issue.1, pp.77-82, 2009. ,
DOI : 10.1200/JCO.2009.22.1077
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study, Journal of Clinical Oncology, vol.23, issue.13, pp.2988-2995, 2005. ,
DOI : 10.1200/JCO.2005.06.156
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group, Annals of Oncology, vol.16, issue.11, pp.1762-1771, 2005. ,
DOI : 10.1093/annonc/mdi366
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial, JNCI Journal of the National Cancer Institute, vol.100, issue.2, pp.121-133, 2008. ,
DOI : 10.1093/jnci/djm287
URL : http://jnci.oxfordjournals.org/cgi/content/short/100/2/121
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer, Journal of Clinical Oncology, vol.27, issue.15, pp.2474-2481, 2009. ,
DOI : 10.1200/JCO.2008.19.2567
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735, Journal of Clinical Oncology, vol.27, issue.8, pp.1177-1183, 2009. ,
DOI : 10.1200/JCO.2008.18.4028
Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197, Journal of Clinical Oncology, vol.26, issue.25, pp.4092-4099, 2008. ,
DOI : 10.1200/JCO.2008.16.7841
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.11, pp.805-814, 2008. ,
DOI : 10.1093/jnci/djn151
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG), Breast Cancer Research and Treatment, vol.353, issue.1, pp.95-104, 2010. ,
DOI : 10.1007/s10549-009-0468-0
URL : https://hal.archives-ouvertes.fr/hal-00535384
Sequential epirubicindocetaxel-CMF as adjuvant therapy for node-positive early breast cancer: updated results of the TAXIt216 randomized trial, Ann Oncol, vol.19, p.1820, 2008. ,
13:R109 http://breast-cancer-research.com/content, Breast Cancer Research, vol.136, 2011. ,
Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.516, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.516
Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1???3 positive lymph nodes, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.515, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.515
Benefit of taxanes as adjuvant chemotherapy for early breast cancer, Cancer, vol.353, issue.suppl 1, pp.2337-2344, 2006. ,
DOI : 10.1002/cncr.21886
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials, Journal of Clinical Oncology, vol.26, issue.1, pp.44-53, 2008. ,
DOI : 10.1200/JCO.2007.11.3787
Taxanes for adjuvant treatment of early breast cancer, Cochrane Database Syst Rev, vol.266, issue.24, p.4421, 2007. ,
DOI : 10.1002/14651858.CD004421.pub2
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen, Annals of Oncology, vol.17, issue.8, pp.1205-1212, 2006. ,
DOI : 10.1093/annonc/mdl135
Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis, Journal of Clinical Oncology, vol.26, issue.16, pp.2636-2643, 2008. ,
DOI : 10.1200/JCO.2007.14.9146
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer, New England Journal of Medicine, vol.357, issue.15, pp.1496-1506, 2007. ,
DOI : 10.1056/NEJMoa071167
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial, Journal of Clinical Oncology, vol.27, issue.8, pp.1168-1176, 2009. ,
DOI : 10.1200/JCO.2008.18.1024
Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.17, pp.2809-2815, 2009. ,
DOI : 10.1200/JCO.2008.18.2808
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer, Breast Cancer Research and Treatment, vol.27, issue.8, pp.149-157, 2010. ,
DOI : 10.1007/s10549-009-0663-z
URL : https://hal.archives-ouvertes.fr/hal-00535419
BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy, Clinical Cancer Research, vol.16, issue.15, pp.3988-3997, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-0079
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis, Cancer Res, vol.65, pp.767-779, 2005. ,
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001. ,
DOI : 10.1073/pnas.191367098
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, pp.1504-1513, 2007. ,
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, pp.323-334, 2008. ,
DOI : 10.1016/j.breast.2008.02.002
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients, Breast Cancer Research and Treatment, vol.94, issue.11, pp.233-240, 2008. ,
DOI : 10.1007/s10549-007-9590-z
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy, Breast Cancer Research, vol.15, issue.5, p.69, 2009. ,
DOI : 10.2174/092986708783769759
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study, Clin Cancer Res, vol.9, pp.686-692, 2003. ,
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer, Clin Cancer Res, vol.6, pp.3103-3110, 2000. ,
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.24, issue.23, pp.3726-3734, 2006. ,
DOI : 10.1200/JCO.2005.04.7985
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.3, pp.207-212, 2008. ,
DOI : 10.1093/jnci/djm289
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601), The Lancet Oncology, vol.11, issue.3, pp.266-274, 2010. ,
DOI : 10.1016/S1470-2045(10)70006-1
Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, Journal of Clinical Oncology, vol.23, issue.16, pp.3686-3696, 2005. ,
DOI : 10.1200/JCO.2005.10.517
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer, JAMA, vol.295, issue.14, pp.1658-1667, 2006. ,
DOI : 10.1001/jama.295.14.1658
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose???dense sequential adjuvant chemotherapy, Breast Cancer Research and Treatment, vol.19, issue.3, pp.251-261, 2006. ,
DOI : 10.1038/sj.onc.1203685
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?, The Breast, vol.18, pp.131-134, 2009. ,
DOI : 10.1016/S0960-9776(09)70287-5
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer, Clinical Cancer Research, vol.13, issue.7, pp.2061-2067, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2078
Predictive factors for response to docetaxel in human breast cancers, Cancer Science, vol.20, issue.9, pp.813-820, 2006. ,
DOI : 10.1002/cncr.20203
Specific P53 mutations are associated with de Jacquemier et al. Breast Cancer Research http://breast-cancer-research.com/content/13/6/R109 novo resistance to doxorubicin in breast cancer patients, Nat Med, vol.13, issue.2, pp.109811-814, 1996. ,
DOI : 10.1038/nm0796-811
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis, Nature Medicine, vol.48, issue.1, pp.72-79, 1996. ,
DOI : 10.1038/nm0196-72
Gene expression profiling of breast cancer, Breast Cancer Research, vol.27, issue.S3, p.11, 2009. ,
DOI : 10.1200/JCO.2008.21.6887
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Annals of Oncology, vol.22, issue.8, pp.1736-1747, 2011. ,
DOI : 10.1093/annonc/mdr304
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.736-750, 2009. ,
DOI : 10.1093/jnci/djp082
Proliferation Marker Ki-67 in Early Breast Cancer, Journal of Clinical Oncology, vol.23, issue.28, pp.7212-7220, 2005. ,
DOI : 10.1200/JCO.2005.07.501
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole, Journal of Clinical Oncology, vol.26, issue.34, pp.5569-5575, 2008. ,
DOI : 10.1200/JCO.2008.17.0829
Ki67 in breast cancer: prognostic and predictive potential, The Lancet Oncology, vol.11, issue.2, pp.174-183, 2010. ,
DOI : 10.1016/S1470-2045(09)70262-1
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data, Statistics in Medicine, vol.10, issue.19, pp.2595-2609, 2000. ,
DOI : 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M
1186/bcr3051 Cite this article as Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC -PACS 01 randomized trial, Breast Cancer Research, vol.13, pp.10-109, 2011. ,